by Raynovich Rod | Mar 2, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 nice broad biotech rally on stimulus hopes with biotech now seen as possible solution https://www.barrons.com/articles/the-dow-is-up-900-points-after-congress-agrees-on-8-3-billion-package-to-battle-coronavirus-51583350527?mod=hp_LATEST XBI up over 3%to $93...
by Raynovich Rod | Jan 16, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Momentum is Easing in Biotech -Is the JPMorgan rally Over? We need to see which stocks hold up when momentum decelerates. it has been a good run for the week but not too frothy.We are “content challenged” in that we sat through three days of interesting...
by Raynovich Rod | Jan 14, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
JPM Notes #2 : Investors buy into Life science innovation After a lackluster day Monday the tape for JPM life science sector stocks picked up with a decent rally. Major ETFs reversed the trend from yesterday with the IBB up 1.64% and the XBI up 2.94% despite NASDAQ...
by Raynovich Rod | Jan 13, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 1/14/2 12:30 EDT…Very Bullish Tape today–Update at Close IBB up 1.27% , XBI up 2.47%. Gene therapy stocks are on a tear even before BLUE and EDIT (both up >5%) present later today and tomorrow. ===== J.P.Morgan Healthcare Conference Notes #1:...
by Raynovich Rod | Nov 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/20…China Phase 1 deal stalled -curbs strong momentum in biopharma. Amarin (AMRN) getting beat up by an Oppenheimer skeptic who thinks Vascepa growth will be tepid. Despite tape slowing many stocks saw huge gains: ASND NKTR SRPT etc. Per comment on...
by Raynovich Rod | Oct 31, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-2 Genmark (GNMK) down 3.6 % to $5.61 on Q3 results. Beat on revenue to $20.9 M up 32 % over prior quarter, loss of 20 cents/share.Waiting for a buy-out in 2020? Update-1 …Nov. 1…All of these picks are up today, IWM is up 1.6%, IJR is up...
by Raynovich Rod | Oct 23, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/25 at close…A Good Day on Low Volume-NASDAQ up 0.7%, S&P is up 20.56% YTD! Large caps mixed with IBB down a tad 0.29%;leaders are BIIB,BMY,RHHBY NASDAQ-100 at record high; QQQ up 0.8% to $195.64. Gilead Sciences (GILD) a big loser on earnings...
by Raynovich Rod | Oct 21, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 10/22. Some follow through in biotech rally but sold off mirroring the NASDAQ about 2p,Maybe BREXIT related but we’ll see later this week after many earnings reports. Large caps have been leading and although the IBB was up 1.66% it sold off from $107...
by Raynovich Rod | Oct 2, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-2 10/4 Broad Rally day: all major averages up 1.4%, NAZ at 7982. Risk back on. But biotech lags major indices IBB up 0.75%, XBI up 0.21% to $76.82. Better trade for biotech has been large caps: ABBV, AMGN, MRK,RHHBY VRTX. Mid-cap movers: BLUE up 3.97%, GWPH up...
by Raynovich Rod | Sep 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 A bit of a sell-off on end of week option expirations and cancellation of China visit to farm Bureau in MT. NAZ down 0.8%, S&P down 0.5%. Less reaction to China news now? Can biotech rally as contrian play to tech and industrials? tape in biotech was...